Last reviewed · How we verify
grazoprevir and elbasvir — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
grazoprevir and elbasvir (grazoprevir and elbasvir) — Taoyuan General Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| grazoprevir and elbasvir TARGET | grazoprevir and elbasvir | Taoyuan General Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- grazoprevir and elbasvir CI watch — RSS
- grazoprevir and elbasvir CI watch — Atom
- grazoprevir and elbasvir CI watch — JSON
- grazoprevir and elbasvir alone — RSS
Cite this brief
Drug Landscape (2026). grazoprevir and elbasvir — Competitive Intelligence Brief. https://druglandscape.com/ci/grazoprevir-and-elbasvir. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab